Posted on by Cynthia Johnson

Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)

NCT#: & LinkNCT05607550
NCT QR Code
Available as of:July 15 2024
Contract:Caris
Indication Category:Lung
Study Sponsor:ArriVent BioPharma
Protocol #:FURMO-004
Title:Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)
Highlight Details:***REFERRAL ONLY***A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations
Biomarkers:EGFR Exon 20 insertion mutation
Indication:NSCLC 
Phase:3
Treatment Line:
Study Drug/Test Compound:Furmonertinib
Notes
Recruitment Status:Just In Time
Participating Institution:Salinas Valley Health
Salinas Valley Health Clinical Research Program:Terri Nielsen, MSJ, RN, CCRP, Clinical Research Program Manager, [email protected]